Tag Archive for ‘non-small cell lung cancer’
The evolution of lung cancer surgery contributes to the sharpest drop in overall cancer mortality in the U.S.
This article describes the advancements in early detection and surgical treatment of lung cancer that led to improved lung cancer survival from a thoracic surgeon’s perspective.
ALCHEMIST trial has potential to improve outcomes after lung cancer resection
The ALCHEMIST CHEMO-IO is a trial for patients with early-stage non-small cell lung cancer (NSCLC) with the potential to change the way patients with resected NSCLC are treated.
In search of the philosopher’s stone: The ALCHEMIST study for lung cancer
This month’s column provides an update on the ALCHEMIST trials for patients with operable lung cancer, including the addition of a third arm to study, which permits the inclusion of patients without ALK or EGFR mutations.
Biomarker-driven adjuvant targeted therapy for NSCLC—the ALCHEMIST trials
This month’s column summarizes the ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) platform and how it facilities definitive studies of adjuvant targeted therapies in biomarker-selected non-small cell lung cancer patients.
Limited resection as a cure for early lung cancer: Time to challenge the gold standard?
A clinical trial is exploring whether limited resection should replace lobectomy as the gold standard for treatment of early-stage lung cancer.
Alliance leads thoracic surgery trials for lung cancer in 2012
Two lung surgery clinical trials are currently being conducted through the Alliance for Clinical Trials in Oncology. These two trials are highlighted in the accompanying diagram (see Figure) with an algorithm to assist in decision making and patient eligibility. The surgical standard of care for early-stage non-small cell lung cancer (NSCLC) is an anatomic lobectomy […]